TY - JOUR
T1 - Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials
T2 - Longitudinal Item Response Theory Models
AU - Luo, Sheng
AU - Zou, Haotian
AU - Goetz, Christopher G.
AU - Choi, Dongrak
AU - Oakes, David
AU - Simuni, Tanya
AU - Stebbins, Glenn T.
N1 - Funding Information:
S.L. reports the following: consulting and advisory board membership with honoraria with the National Institutes of Health and CHDI Management, Inc.; grants and research from the National Institutes of Health, CHDI, International Parkinson and Movement Disorder Society, and Parkinson's Foundation; honoraria from St. Jude Children's Hospital; and a salary from Duke University. H.Z. reports a salary from University of North Carolina at Chapel Hill. C.G.G. reports the following: funding to Rush University Medical Center from the National Institutes of Health, Department of Defense, and The Michael J. Fox Foundation for research conducted by Dr. Goetz; presidential stipend from the International Parkinson and Movement Disorder Society paid to Rush University Medical Center as part of Dr. Goetz's salary; faculty stipends from the American Academy of Neurology; guest professorship honorarium provided by the University of Chicago and NorthShore University Health System; royalties from Elsevier Publishers and Wolters Kluwer Publishers; and a salary from Rush University Medical Center. D.C. reports a salary from Duke University. D.O. reports the following: data and safety monitoring board of University of Pennsylvania; grants/research from the National Institutes of Health, The Michael J. Fox Foundation, and Grey Matter Technology; royalties from Springer and Taylor and Francis; and a salary from University of Rochester Medical Center. T.S. reports the following: consulting or advisory board membership with honoraria from Acadia, Abbvie, Accorda, Adamas, Allergan, Amneal, Aptinyx, Denali, General Electric (GE), Kyowa, Neuroderm, Neurocrine, Sanofi, Sinopia, Sunovion, Roche, Takeda, Voyager, and US World Meds; grants/research from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Abbvie, IMPAX, Prevail, National Institute of Neurological Disorders and Stroke (NINDS), Michael J. Fox Foundation for Parkinson's Research (MJFF), and the Parkinson's Foundation; honoraria from Sanofi; and a salary from Northwestern University. G.T.S. reports the following: consulting and advisory board membership with honoraria from Acadia, Pharmaceuticals, Adamas Pharmaceuticals, Inc., Biogen, Inc., Ceregene, Inc., CHDI Management, Inc., Cleveland Clinic Foundation, Ingenix Pharmaceutical Services (i3 Research), MedGenesis Therapeutix, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Tools‐4‐Patients, Ultragenyx, Inc., and the Sunshine Care Foundation; grants and research from the National Institutes of Health, Department of Defense, The Michael J. Fox Foundation for Parkinson's Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, and CBD Solutions; honoraria from the International Parkinson and Movement Disorder Society, American Academy of Neurology, The Michael J. Fox Foundation for Parkinson's Research, Food and Drug Administration, National Institutes of Health, and the Alzheimer's Association; and a salary from Rush University Medical Center.
Funding Information:
The research of Sheng Luo was supported by National Institute on Aging (Grant R01AG064803). The Rush Parkinson's Disease and Movement Disorders Program is a designated Clinical Center of Excellent supported by the Parkinson Foundation. The authors have no conflicts of interest to report.
Publisher Copyright:
© 2021 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Although nontremor and tremor Part 3 Movement Disorder Society–Unified Parkinson's Disease Rating Scale items measure different impairment domains, their distinct progression and drug responsivity remain unstudied longitudinally. The total score may obscure important time-based and treatment-based changes occurring in the individual domains. Objective: Using the unique advantages of item response theory (IRT), we developed novel longitudinal unidimensional and multidimensional models to investigate nontremor and tremor changes occurring in an interventional Parkinson's disease (PD) study. Method: With unidimensional longitudinal IRT, we assessed the 33 Part 3 item data (22 nontremor and 10 tremor items) of 336 patients with early PD from the STEADY-PD III (Safety, Tolerability, and Efficacy Assessment of Isradipine for PD, placebo vs. isradipine) study. With multidimensional longitudinal IRT, we assessed the progression rates over time and treatment (in overall motor severity, nontremor, and tremor domains) using Markov Chain Monte Carlo implemented in Stan. Results: Regardless of treatment, patients showed significant but different time-based deterioration rates for total motor, nontremor, and tremor scores. Isradipine was associated with additional significant deterioration over placebo in total score and nontremor scores, but not in tremor score. Further highlighting the 2 separate latent domains, nontremor and tremor severity changes were positively but weakly correlated (correlation coefficient, 0.108). Conclusions: Longitudinal IRT analysis is a novel statistical method highly applicable to PD clinical trials. It addresses limitations of traditional linear regression approaches and previous IRT investigations that either applied cross-sectional IRT models to longitudinal data or failed to estimate all parameters simultaneously. It is particularly useful because it can separate nontremor and tremor changes both over time and in response to treatment interventions.
AB - Background: Although nontremor and tremor Part 3 Movement Disorder Society–Unified Parkinson's Disease Rating Scale items measure different impairment domains, their distinct progression and drug responsivity remain unstudied longitudinally. The total score may obscure important time-based and treatment-based changes occurring in the individual domains. Objective: Using the unique advantages of item response theory (IRT), we developed novel longitudinal unidimensional and multidimensional models to investigate nontremor and tremor changes occurring in an interventional Parkinson's disease (PD) study. Method: With unidimensional longitudinal IRT, we assessed the 33 Part 3 item data (22 nontremor and 10 tremor items) of 336 patients with early PD from the STEADY-PD III (Safety, Tolerability, and Efficacy Assessment of Isradipine for PD, placebo vs. isradipine) study. With multidimensional longitudinal IRT, we assessed the progression rates over time and treatment (in overall motor severity, nontremor, and tremor domains) using Markov Chain Monte Carlo implemented in Stan. Results: Regardless of treatment, patients showed significant but different time-based deterioration rates for total motor, nontremor, and tremor scores. Isradipine was associated with additional significant deterioration over placebo in total score and nontremor scores, but not in tremor score. Further highlighting the 2 separate latent domains, nontremor and tremor severity changes were positively but weakly correlated (correlation coefficient, 0.108). Conclusions: Longitudinal IRT analysis is a novel statistical method highly applicable to PD clinical trials. It addresses limitations of traditional linear regression approaches and previous IRT investigations that either applied cross-sectional IRT models to longitudinal data or failed to estimate all parameters simultaneously. It is particularly useful because it can separate nontremor and tremor changes both over time and in response to treatment interventions.
KW - Bayesian modeling
KW - Parkinson's disease
KW - clinimetrics
KW - disease progression
KW - longitudinal data
UR - http://www.scopus.com/inward/record.url?scp=85111681445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111681445&partnerID=8YFLogxK
U2 - 10.1002/mdc3.13311
DO - 10.1002/mdc3.13311
M3 - Article
C2 - 34631944
AN - SCOPUS:85111681445
SN - 2330-1619
VL - 8
SP - 1083
EP - 1091
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 7
ER -